
BMS’ Opdivo fails to improve overall survival in small-cell lung cancer
pharmafile | October 15, 2018 | News story | Research and Development, Sales and Marketing | BMS< Opdivo, Bristol-Myers Squibb, Cancer, lung cancer, pharma
Bristol-Myers Squibb’s Opdivo (nivolumab) failed to deliver on its primary endpoint in a Phase 3 study in small-cell lung cancer, failing to significantly improve overall survival (OS) in patients who had relapsed following platinum-based chemotherapy.
The trial examined the drug’s efficacy in two randomised groups, with one receiving Opdivo and the other using either topotecan or amrubicin. The primary endpoint was OS, while secondary endpoints included progression-free survival and objective response rates.
Despite being found to not provide sufficient OS benefit versus chemotherapy alone in this indication, the study found the safety profile of the PD-1 inhibitor to be consistent with previous findings.
“Small cell lung cancer is a highly aggressive disease in which significant unmet need remains,” commented Dr Sabine Maier, Development Lead, Thoracic Cancers, Bristol-Myers Squibb. “We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer. We thank the patients, their families, and the physicians involved in the CheckMate -331 study.”
Matt Fellows
Related Content

Cizzle Biotechnology expands US rollout of lung cancer blood test
Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung …

SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer
The Scottish Medicines Consortium (SMC) has accepted Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) for …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …






